Better Therapeutics, Inc. develops prescription digital therapeutics that delivers behavioral therapy, and creates feedback mechanisms using remotely monitored and patient-generated data. Its products include Nutritional Cognitive Behavioral Therapy (Nutritional CBT), behavioral therapy for patients with type 2 diabetes and other cardiometabolic diseases. It also manufactures therapeutic medicines, such as BTÂ001, BTÂ002, BTÂ003, BTÂ004, and BTÂ005 for cardiometabolic diseases. The company was incorporated in 2015 and is based in San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: bettertx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $17.00 | Buy | Chardan Capital Markets |
| 11/10/2021 | Outperform | Cowen |